• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:冯会,高峰,王浩铭,王文华,刘莲花,刘庆涛,黄丙俭.PEG-rhG-CSF次级预防对全脑全脊髓放疗致血液学毒性的临床疗效观察[J].药学研究,2021,40(1):56-59[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2676次   下载 2446次 本文二维码信息
码上扫一扫!
PEG-rhG-CSF次级预防对全脑全脊髓放疗致血液学毒性的临床疗效观察
冯会,高峰,王浩铭,王文华,刘莲花,刘庆涛,黄丙俭
字体:加大+|默认|缩小-
(临沂市肿瘤医院放疗一科,山东 临沂 276000)
摘要:
目的 观察聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)次级预防在全脑全脊髓放疗过程中对患者血液学毒性的治疗疗效及对放疗疗程的影响。方法 回顾性分析了15例中枢神经系统肿瘤患者在接受全脑全脊髓放疗期间次级预防应用PEG-rhG-CSF对血液学毒性的治疗效果,观察比较性别、年龄、诊断的血液学毒性差异,并探讨了次级预防应用PEG-rhG-CSF对放疗进程的影响。结果 全脑全脊髓放疗期间次级预防应用PEG-rhG-CSF,15例患者中,所有患者均有不同程度的骨髓抑制;其中I度减低有3例(20.0%),Ⅱ度有8例(53.3%),Ⅲ度有2例(13.3%),Ⅳ度有2例(13.3%)。有10例(66.7%)出现血小板减少,其中I度减低的有5例(33.3%),Ⅱ度有3例(20%),Ⅲ度有2例(13.3%),无Ⅳ度减低。5例(33.3%)出现血红蛋白下降,I度的有3例(20.0%),Ⅱ度有2例(13.3%),无Ⅲ度减低。白细胞、血小板、血红蛋白Ⅲ~Ⅳ级骨髓抑制分别为26.7%、13.3%、0.0%。2例 (13.3%)患者因重度血液学毒性中断治疗,中断时间7~8 d,治疗中断的比率为13.3%。次级预防应用PEG-rhG-CSF减少了因血液学毒性引起的放疗暂停的发生。结论 全脑全脊髓放疗出现血液学毒性常见,大部分患者在次级预防应用PEG-rhG-CSF支持下显著减少Ⅲ~Ⅳ级骨髓抑制的发生,从而减少了放疗疗程的延长,保证大部分患者顺利完成了放疗疗程。该方法值得在全脑全脊髓放疗中进一步研究并推广应用。
关键词:  全脑全脊髓照射  聚乙二醇化重组人粒细胞刺激因子  血液学毒性
DOI:10.13506/j.cnki.jpr.2021.01.011
基金项目:
Clinical observation of PEG-rhG-CSF secondary prevention on hematological toxicity caused by whole brain and spinal cord radiotherapy
FENG Hui,GAO Feng,WANG Haoming,WANG Wenhua,LIU Lianhua,LIU Qingtao,HUANG Bingjian
(First Department of Radiotherapy,Linyi Cancer Hospital,Linyi 276000,China)
Abstract:
ObjectiveThe primary goal of this study is to observe the effect brought by secondary prevention with pegylated recombinant human granulocyte-colony stimulating factor (PEG-rhG-CSF) on hematological toxicity and therapy period in whole brain and whole bone marrow radiotherapy.MethodsWe did a rhetorical analysis on 15 patients with tumors on the central neural system (CNS),who were treated with PEG-rhG-CSF for secondary prevention during whole brain and whole bone marrow radiotherapy, to study the effects of such substance on hematological toxicity.Furthermore, we compared the variance in toxicity based on differences in gender,age as well as diagnostic results.Finally,we discussed the outcomes using PEG-rhG-CSF on the radiotherapy during secondary prevention.ResultsWe found that all the 15 patients suffered different degrees of myelosuppression. The corresponding number of patients were 3 (20.0%), 8 (53.3%), 2 (13.3%), 2 (13.3%) for degree I, II, III and IV, respectively. Among the 15 patients, 10 exhibited a decrease in platelet count, where 5 (33.3%), 3 (20%), 2 (13.3%) showed a degree I, II, III decline, respectively. None of them exhibited a degree IV decline in platelets.Additionally,5 of the total 15 patients demonstrated a drop in hemoglobin levels, where 3 of them were degree I and 2 were degree II, with no one suffering degree III decline.Patients showing myelosuppression at degree III or IV as revealed through decreased leukocyte, platelet and hemoglobin levels consisted of 26.7%,13.3% and 0.0% of the total number,respectively.2 patients (13.3%) experienced an interruption, which lasted for 7-8 days, in their treatment due to severe hematological toxicity.Secondary prevention by the application of PEG-rhG-CSF can reduce the interruption resulted from hematological toxicity during radiotherapy.ConclusionIn a word,it is quite common for patients undergoing whole brain and whole bone marrow radiotherapy to exhibit hematological toxicity. With the help of PEG-rhG-CSF during secondary prevention, myelosuppression at degree III or IV is significantly reduced among the majority of such patients, shortening the radiotherapy period and ensuring their completion of the therapy. Therefore, the introduction of PEG-rhG-CSF in secondary prevention is worthy to be further studied and spread for a wider range of applications.
Key words:  Whole brain and whole bone marrow radiotherapy  PEG-rhG-CSF  Blood
今日访问量:2644    总访问量:55339159
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司